Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
163.6 EUR | +2.12% | +1.24% | +13.53% |
Mar. 26 | UBS Raises Merck KGaA PT, Keeps Buy Rating | MT |
Mar. 26 | MERCK KGAA : Jefferies keeps its Buy rating | ZD |
Sales 2024 * | 21.29B 22.94B | Sales 2025 * | 22.55B 24.3B | Capitalization | 71.13B 76.65B |
---|---|---|---|---|---|
Net income 2024 * | 2.97B 3.2B | Net income 2025 * | 3.45B 3.72B | EV / Sales 2024 * | 3.65 x |
Net Debt 2024 * | 6.51B 7.01B | Net Debt 2025 * | 4.44B 4.79B | EV / Sales 2025 * | 3.35 x |
P/E ratio 2024 * |
24.1
x | P/E ratio 2025 * |
20.5
x | Employees | 62,908 |
Yield 2024 * |
1.36% | Yield 2025 * |
1.47% | Free-Float | 29.71% |
Latest transcript on Merck KGaA
1 day | +2.12% | ||
1 week | +1.24% | ||
Current month | +3.68% | ||
1 month | +2.99% | ||
3 months | +14.77% | ||
6 months | +4.97% | ||
Current year | +13.53% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 20-07-12 | |
Director of Finance/CFO | 53 | 19-04-25 | |
Laura Matz
CTO | Chief Tech/Sci/R&D Officer | - | 18-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 75 | 14-05-08 | |
Christian Raabe
BRD | Director/Board Member | - | - |
Chairman | 67 | 19-04-25 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.34% | 2 M€ | +13.56% | - | |
2.01% | 0 M€ | 0.00% | - | |
1.80% | 962 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 163.6 | +2.12% | 371,656 |
24-03-27 | 160.2 | +0.69% | 299,813 |
24-03-26 | 159.1 | -0.31% | 255,538 |
24-03-25 | 159.6 | -1.36% | 165,432 |
24-03-22 | 161.8 | +0.12% | 209,833 |
Delayed Quote Xetra, March 28, 2024 at 12:35 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.53% | 76.83B | |
+13.52% | 9.63B | |
-7.87% | 5.37B | |
+12.50% | 4.28B | |
+18.09% | 3.71B | |
+42.95% | 2.91B | |
-19.01% | 2.54B | |
-20.66% | 2.37B | |
+17.86% | 1.87B | |
-0.50% | 1.64B |